Reference:
Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., et al. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine, 385, 1761-73. https://doi.org/10.1056/NEJMoa2110345
Summary:
This supplementary appendix provides detailed data related to the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, as explored in the main study. Ethical guidelines were adhered to during the trial, which involved a comprehensive testing regime for SARS-CoV-2. The study monitored participants for adverse events and assessed vaccine efficacy over a six-month period. Key findings indicated a significant reduction in COVID-19 incidence and severe cases among vaccinated individuals compared to the placebo group. Data collection included demographic information, comorbidities, and adverse events, ensuring a robust analysis of vaccine performance across diverse populations. The results support the vaccine’s effectiveness in preventing COVID-19 and highlight the importance of ongoing monitoring for safety and efficacy.